Pfizer off-patent division to merge with Mylan

Pfizer is to merge its off-patent drug business Upjohn with Mylan, in a deal that will see Pfizer shareholders own 57% of the new company.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

90% of essential medicines off-patent, study reveals

10 December 2020 Only 10% of essential medicines recommended by the World Health Organisation are on patent, according to a report by research and advocacy organisation, the Geneva Network.

Americas

Former FDA head takes place on Pfizer board

28 June 2019 Pfizer has appointed former US Food and Drug Administration commissioner Scott Gottlieb to its board.

Big Pharma

Pfizer to acquire Array BioPharma for $11.4bn

17 June 2019 US biopharmaceutical company Pfizer has entered agreed to acquire Array BioPharma, a biotechnology company which develops small molecule drugs for the treatment of cancer.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Pfizer off-patent division to merge with Mylan

More on this story

Editor's picks

Editor's picks

More features